Neu-botulinum Toxin Type A (Neuronox(R) - botulinum toxin type A product by medyceles company , Korea) 50 units Intramuscular injection in the affected neck muscle that cause cervical dystonia every 12 weeks for 24 weeks ( 2 times , 12 week interval)

Abo-botulinum Toxin Type A (Dysport (R) - botulinum toxin type A product by IPEN company, France ) 250 unit Intramuscular Injection in the affected neck muscle that cause cervical dystonia every 12 weeks for 24 weeks (2 times , 12 week interval)

Cervical Dystonia

Injection botulinum toxin intramuscular for affected neck muscle

Neuronox(R)

Dysport (R)

Assistant Professor Subsai Kongsaengdao

Lampang Hospital

Surat Thani hospital

Sappasithiprasong Hospital

Abobotulinum Toxin and Neubotulinum Toxin Injection in Cerivical Dystonia

A 48-Week Prospective, Double-Blinded, Randomized, Cross-over Design in Multicenter Study of 250 Unit of Dysport Versus 50 Unit of Neuronox Injection For Cervical Dystonia in Thai Patients

TWSTRS ranged( 0-85 by summation of all 3 sub- scales ) higher represent a worse outcome TWSTRS Sub- scale includes
TWSTRS-Total severity scale ( maximum 35 points)
TWSTS-Disability scale (maximum 30 points)
TWSTS-Pain scale (maximum 20 points)

) Cervical Dystonia Impact Profile-58 items composed of 8 sub-scale Total score by summation of 8 subscale higher represent a worse outcome Analysis both total score (range 58-290 points) And sub-scale analysis composed of Head and neck symptoms ( 6 items ; 6-30 points) Pain and discomfort ( 5 items ; 5-25 points) Upper limb activity ( 9 items ; 9-45 points) Walking ( 9 items ; 9-45 points) Sleep ( 4 items ; 4-20 points) Annoyance ( 8 items ; 8-40 points) Mood (7 items ; 7-35 points) Psychosocial functioning ( 10 items ; 10-50 points)

Comparesion the quality of life (SF 36) pre- and post- 12 and 24 week ttreatment with 50 unit of Neubotulinum Toxin Type A (Neuronox) and 250 unit of Abobotulinum Toxin Type A (Dysport) this score has special formula calculation

Comparesion of CES-D pre- and post- 12 and 24 week treatment with 50 unit of Neubotulinum Toxin Type A (Neuronox) and 250 unit of Abobotulinum Toxin Type A (Dysport) Score ranged from 20-80 points higher represent a worse outcome

Comparesion of PHQ-9 pre- and post- 12 and 24 week treatment with 50 unit of Neubotulinum Toxin Type A (Neuronox) and 250 unit of Abobotulinum Toxin Type A (Dysport) There is the special scale calculation for diagnosis Major depressive disorder, Other depressive disorder and others,higher points /score represent a worse outcome ranged 0-27 points plus 3 points Total summation of 5-9 points indicate Minimal symptoms, 10-14 Minor depression ++ or Dysthymia* or Major depression, mild , 15-19 points Major depression, moderately severe
≥ 20 Major depression, severe

Comparesion of CGIC pre- and post- 12 and 24 week treatment with 50 unit of Neubotulinum Toxin Type A (Neuronox) and 250 unit of Abobotulinum Toxin Type A (Dysport)

Dr Subsai Kongsaengdao

Associated Professor

Rajavithi Hospital

Patients with Convergence Insufficiency in Active Vision Therapy

Subjects with Normal Binocular Vision will receive a therapy that appears to be therapeutic but does not have any binocular coordination benefits.

Convergence Insufficiency

Exercises that will stimulate disparity vergence or accommodation independently and then combined will be used.

Office Based Vergence and Accommodative Therapy

NJIT

Neural Mechanism of Vision Therapy for Patients With Convergence Insufficiency

Functional Neural Mechanism of Vision Therapy for Patients With Convergence Insufficiency

how accurate a patient can fixate on a new target

At this time there is no plan in place because the eye movement data collected will be in a proprietary format

Dr. Tara Lynn Alvarez

Professor

New Jersey Institute of Technology

National Eye Institute (NEI)

Clinician did not know which treatment group. Subjects did not know which treatment group

BOTOX®, Allergan treatment in 2 mL of saline solution (0.9% NaCl) treatment

2 mL of saline solution (0.9% NaCl) treatment

Trigeminal Neuropathy, Traumatic

50 U BTX-A (BOTOX®, Allergan) powder diluted in 2 mL saline solution (0.9% NaCl) administrated at visit 2 by intra oral injection

BOTOX®, Allergan

2 mL saline solution (0.9% NaCl) administrated at visit 2 by intra oral injection

Placebo

Groupe Hospitalier Pitié-Salpêtrière

Botulinum Toxin Injections for Oral Neuropathic Pain

Use of Botulinum Toxin (BTX) for the Treatment of Peripheral Painful Traumatic Trigeminal Neuropathy (PPTTN)

Self-reported average pain intensity from each morning's record in a diary concerning the last 24 hours during one week, before and one month after injection

Pain recorded each morning in a diary (diary 2) concerning the last 24 hours, using the 11-point numerical scale (NS; 0 = no pain; 10 = maximal pain imaginable) of the Brief Pain Inventory (BPI) at 1 month, 3 months and 6 months. The least, average, and maximum pain intensity during the 7 days will be collected and compared to baseline.

Items of the neuropathic pain symptom inventory (NPSI) will be recorded during the last 24 hours on 11-points (0-10 points) numerical scales.

Visual Analogic Scale (VAS) (from 0 mm [no pain relief] to 100 mm [maximal pain relief]).

The Clinical Global Impression - Improvement scale (CGI-I) (a 7-point scale rating from very much improved to very much worse) will be used .

The areas of main pain and referred pain will be reported directly from the patient to a soft foil, then digitized for measurement on Image J software.

According to the conclusions of the European task force committee for intraoral quantitative sensory testing (QST), the QST is defined by :
Brush-induced allodynia will be evaluated stroking the skin with a standardized brush and will be considered as present if evoking a clear sensation of pain. The intensity of allodynia will be recorded on a 100 mm visual analog scale. Area of Brush-induced allodynia will be traced on a transparent plastic foil, and then digitized for measurement on Image J software.
Mechanical sensations (detection thresholds to non-painful stimuli) and pain thresholds will be measured with calibrated von Frey hairs (0.06-300gm) (Bioseb, France) (or electronic von Frey, Bioseb France).
Thermal sensations and pain thresholds (in °C) will be assessed with a thermoalgometer (TSA II; Medoc, Israel) with an intraoral thermode by the method of limits, with baseline temperatures adjusted to the patient's skin temperature .

Emotional state using the Hospital Anxiety and Depression Scale (HADS) including 14 items scored as anxiety and depression scores (each on 21)

Emotional state using items of the Brief Pain Inventory (BPI).

Interference with oral function will be measured with the Brief Pain Inventory (BPI) (with the exclusion of the item "ability to walk" changed for "ability to chew" judged more relevant here) rated from 0 (does not interfere) to 10 (complete interference).

Quality of life will be assessed with specific questionnaires Geriatric Oral Health Assessment Index (GOHAI)

Quality of life will be assessed with specific Oral Health Impact Profile (OHIP)

Safety of BTX-A, particularly for potential systemic adverse effects, will be assessed throughout the study. Adverse events will be declared in the case report form (CRF).

Pain related to injections will be rated as mild, moderate, or severe.

measurement of the time course of the pain throughout the day with a diary (diary 1) in which the patient reports his/her pain every hour on a numeric scale (0-10) during 7 days.

strabismus/headache

Abobotulinum Toxin and Neubotulinum Toxin Injection in Cerivical Dystonia

Neural Mechanism of Vision Therapy for Patients With Convergence Insufficiency

Botulinum Toxin Injections for Oral Neuropathic Pain

科学支持的最完整的草药数据库